Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Patient awareness about family planning represents a major knowledge gap in multiple sclerosis.

Rasmussen PV, Magyari M, Moberg JY, Bøgelund M, Jensen UFA, Madsen KG.

Mult Scler Relat Disord. 2018 Jun 15;24:129-134. doi: 10.1016/j.msard.2018.06.006. [Epub ahead of print]

PMID:
30005355
2.

Early versus later treatment start in multiple sclerosis: a register-based cohort study.

Chalmer TA, Baggesen LM, Nørgaard M, Koch-Henriksen N, Magyari M, Sorensen PS; Danish Multiple Sclerosis Group.

Eur J Neurol. 2018 May 30. doi: 10.1111/ene.13692. [Epub ahead of print]

PMID:
29847005
3.

Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study.

Boesen MS, Koch-Henriksen N, Thygesen LC, Eriksson F, Greisen G, Born AP, Blinkenberg M, Uldall PV, Magyari M.

Mult Scler. 2018 May 1:1352458518771871. doi: 10.1177/1352458518771871. [Epub ahead of print]

PMID:
29770725
4.

Small-scale geographical variation in multiple sclerosis: A case-control study using Danish register data 1971-2013.

Bihrmann K, Nielsen NM, Magyari M, Koch-Henriksen N, Nordsborg RB, Ersbøll AK.

Mult Scler Relat Disord. 2018 May 4;23:40-45. doi: 10.1016/j.msard.2018.04.021. [Epub ahead of print]

5.

Implications of the International Paediatric Multiple Sclerosis Study Group consensus criteria for paediatric acute disseminated encephalomyelitis: a nationwide validation study.

Boesen MS, Blinkenberg M, Koch-Henriksen N, Thygesen LC, Uldall PV, Magyari M, Born AP.

Dev Med Child Neurol. 2018 May 10. doi: 10.1111/dmcn.13798. [Epub ahead of print]

PMID:
29744874
6.

Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women.

Koch-Henriksen N, Thygesen LC, Stenager E, Laursen B, Magyari M.

Neurology. 2018 May 29;90(22):e1954-e1963. doi: 10.1212/WNL.0000000000005612. Epub 2018 May 2.

PMID:
29720546
7.

Pediatric acquired demyelinating syndromes: a nationwide validation study of the Danish National Patient Register.

Boesen MS, Magyari M, Born AP, Thygesen LC.

Clin Epidemiol. 2018 Apr 10;10:391-399. doi: 10.2147/CLEP.S156997. eCollection 2018.

8.

Progressive multiple sclerosis, cognitive function, and quality of life.

Højsgaard Chow H, Schreiber K, Magyari M, Ammitzbøll C, Börnsen L, Romme Christensen J, Ratzer R, Soelberg Sørensen P, Sellebjerg F.

Brain Behav. 2018 Jan 5;8(2):e00875. doi: 10.1002/brb3.875. eCollection 2018 Feb.

9.

Smoking affects the interferon beta treatment response in multiple sclerosis.

Petersen ER, Oturai AB, Koch-Henriksen N, Magyari M, Sørensen PS, Sellebjerg F, Søndergaard HB.

Neurology. 2018 Feb 13;90(7):e593-e600. doi: 10.1212/WNL.0000000000004949. Epub 2018 Jan 17.

PMID:
29343473
10.

Disability in progressive MS is associated with T2 lesion changes.

Ammitzbøll C, Dyrby TB, Lyksborg M, Schreiber K, Ratzer R, Romme Christensen J, Iversen P, Magyari M, Garde E, Sørensen PS, Siebner HR, Sellebjerg F.

Mult Scler Relat Disord. 2018 Feb;20:73-77. doi: 10.1016/j.msard.2017.12.010. Epub 2017 Dec 18.

PMID:
29324249
11.

Psychiatric morbidity develops after onset of pediatric multiple sclerosis: A Danish nationwide population-based study.

Boesen MS, Thygesen LC, Uldall PV, Eriksson F, Born AP, Blinkenberg M, Koch-Henriksen N, Greisen G, Magyari M.

Mult Scler Relat Disord. 2018 Jan;19:30-34. doi: 10.1016/j.msard.2017.10.018. Epub 2017 Oct 31.

PMID:
29121513
12.

Male factor infertility and risk of multiple sclerosis: A register-based cohort study.

Glazer CH, Tøttenborg SS, Giwercman A, Bräuner EV, Eisenberg ML, Vassard D, Magyari M, Pinborg A, Schmidt L, Bonde JP.

Mult Scler. 2017 Oct 1:1352458517734069. doi: 10.1177/1352458517734069. [Epub ahead of print]

PMID:
29027840
13.

Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.

Thormann A, Sørensen PS, Koch-Henriksen N, Laursen B, Magyari M.

Neurology. 2017 Oct 17;89(16):1668-1675. doi: 10.1212/WNL.0000000000004508. Epub 2017 Sep 20.

PMID:
28931645
14.

Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study.

Koch-Henriksen N, Laursen B, Stenager E, Magyari M.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):626-631. doi: 10.1136/jnnp-2017-315907.

PMID:
28705951
15.

Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: A nationwide population-based incidence study.

Boesen MS, Magyari M, Koch-Henriksen N, Thygesen LC, Born AP, Uldall PV, Blinkenberg M.

Mult Scler. 2018 Jul;24(8):1077-1086. doi: 10.1177/1352458517713669. Epub 2017 Jun 13.

PMID:
28608742
16.

Chronic comorbidity in multiple sclerosis is associated with lower incomes and dissolved intimate relationships.

Thormann A, Sørensen PS, Koch-Henriksen N, Thygesen LC, Laursen B, Magyari M.

Eur J Neurol. 2017 Jun;24(6):825-834. doi: 10.1111/ene.13297.

PMID:
28544411
17.

Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity.

Søndergaard HB, Petersen ER, Magyari M, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2017 Apr;13:25-27. doi: 10.1016/j.msard.2017.01.015. Epub 2017 Jan 31.

PMID:
28427696
18.

Age at Menarche and Risk of Multiple Sclerosis: A Prospective Cohort Study Based on the Danish National Birth Cohort.

Nielsen NM, Harpsøe M, Simonsen J, Stenager E, Magyari M, Koch-Henriksen N, Baker JL, Hjalgrim H, Frisch M, Bager P.

Am J Epidemiol. 2017 Apr 15;185(8):712-719. doi: 10.1093/aje/kww160.

PMID:
28369233
19.

Inverse comorbidity in multiple sclerosis: Findings in a complete nationwide cohort.

Thormann A, Koch-Henriksen N, Laursen B, Sørensen PS, Magyari M.

Mult Scler Relat Disord. 2016 Nov;10:181-186. doi: 10.1016/j.msard.2016.10.008. Epub 2016 Oct 29.

PMID:
27919487
20.

Early safety and efficacy of fingolimod treatment in Denmark.

Voldsgaard A, Koch-Henriksen N, Magyari M, Sellebjerg F, Sørensen PS, Oturai AB.

Acta Neurol Scand. 2017 Jan;135(1):129-133. doi: 10.1111/ane.12573. Epub 2016 Mar 8.

PMID:
27910101
21.

Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.

Nielsen NM, Munger KL, Koch-Henriksen N, Hougaard DM, Magyari M, Jørgensen KT, Lundqvist M, Simonsen J, Jess T, Cohen A, Stenager E, Ascherio A.

Neurology. 2017 Jan 3;88(1):44-51. doi: 10.1212/WNL.0000000000003454. Epub 2016 Nov 30.

22.

The Danish Multiple Sclerosis Treatment Register.

Magyari M, Koch-Henriksen N, Sørensen PS.

Clin Epidemiol. 2016 Oct 25;8:549-552. eCollection 2016. Review.

23.

Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.

Thormann A, Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS.

J Neurol. 2016 Dec;263(12):2484-2493. Epub 2016 Oct 3.

PMID:
27699465
24.

Employment, disability pension and income for children with parental multiple sclerosis.

Moberg JY, Laursen B, Koch-Henriksen N, Thygesen LC, Brødsgaard A, Soelberg Sørensen P, Magyari M.

Mult Scler. 2017 Jul;23(8):1148-1156. doi: 10.1177/1352458516672016. Epub 2016 Sep 28.

PMID:
27682230
25.

Shift work at young age is associated with increased risk of multiple sclerosis in a Danish population.

Gustavsen S, Søndergaard HB, Oturai DB, Laursen B, Laursen JH, Magyari M, Ullum H, Larsen MH, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2016 Sep;9:104-9. doi: 10.1016/j.msard.2016.06.010. Epub 2016 Jun 27.

PMID:
27645354
26.

Educational achievements of children of parents with multiple sclerosis: A nationwide register-based cohort study.

Moberg JY, Magyari M, Koch-Henriksen N, Thygesen LC, Laursen B, Soelberg Sørensen P.

J Neurol. 2016 Nov;263(11):2229-2237. Epub 2016 Aug 19.

PMID:
27541043
27.

High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.

Schreiber K, Magyari M, Sellebjerg F, Iversen P, Garde E, Madsen CG, Börnsen L, Romme Christensen J, Ratzer R, Siebner HR, Laursen B, Soelberg Sorensen P.

Mult Scler. 2017 Apr;23(5):675-685. doi: 10.1177/1352458516661048. Epub 2016 Aug 5.

PMID:
27481206
28.

A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.

Koch-Henriksen N, Magyari M, Sellebjerg F, Soelberg Sørensen P.

Mult Scler. 2017 Feb;23(2):234-241. doi: 10.1177/1352458516643393. Epub 2016 Jul 11.

PMID:
27055806
29.

Gender differences in multiple sclerosis epidemiology and treatment response.

Magyari M.

Dan Med J. 2016 Mar;63(3). pii: B5212. Review.

PMID:
26931196
30.

Self-rated health in women prior to clinical onset of multiple sclerosis: A study within the Danish National Birth Cohort.

Nielsen NM, Harpsøe MC, Simonsen J, Stenager E, Magyari M, Koch-Henriksen N, Frisch M, Bager P.

Mult Scler. 2016 Oct;22(11):1444-1451. Epub 2016 Jan 8.

PMID:
26746810
31.

Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.

Dreyer L, Magyari M, Laursen B, Cordtz R, Sellebjerg F, Locht H.

Ann Rheum Dis. 2016 Apr;75(4):785-6. doi: 10.1136/annrheumdis-2015-208490. Epub 2015 Dec 23. No abstract available.

PMID:
26698850
32.

Physical and social environment and the risk of multiple sclerosis.

Magyari M, Koch-Henriksen N, Pfleger CC, Sørensen PS.

Mult Scler Relat Disord. 2014 Sep;3(5):600-6. doi: 10.1016/j.msard.2014.07.002. Epub 2014 Jul 21.

PMID:
26265272
33.

Role of socio-economic and reproductive factors in the risk of multiple sclerosis.

Magyari M.

Acta Neurol Scand. 2015;132(199):20-3. doi: 10.1111/ane.12426. Review.

PMID:
26046554
34.

Registers of multiple sclerosis in Denmark.

Koch-Henriksen N, Magyari M, Laursen B.

Acta Neurol Scand. 2015;132(199):4-10. doi: 10.1111/ane.12424. Review.

PMID:
26046552
35.

Gender effects on treatment response to interferon-beta in multiple sclerosis.

Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS.

Acta Neurol Scand. 2014 Dec;130(6):374-9. doi: 10.1111/ane.12277. Epub 2014 Sep 10.

PMID:
25208455
36.

The use of valproic acid and multiple sclerosis.

Nielsen NM, Svanström H, Stenager E, Magyari M, Koch-Henriksen N, Pasternak B, Hviid A.

Pharmacoepidemiol Drug Saf. 2015 Mar;24(3):262-8. doi: 10.1002/pds.3692. Epub 2014 Aug 11.

PMID:
25111895
37.

Acute headache and persistent headache attributed to cervical artery dissection: Field testing of ICHD-III beta.

Schytz HW, Ashina M, Magyari M, Larsen VA, Olesen J, Iversen HK.

Cephalalgia. 2014 Aug;34(9):712-716. Epub 2014 Feb 5.

PMID:
24500814
38.

Gender and autoimmune comorbidity in multiple sclerosis.

Magyari M, Koch-Henriksen N, Pfleger CC, Sørensen PS.

Mult Scler. 2014 Aug;20(9):1244-51. doi: 10.1177/1352458514521515. Epub 2014 Feb 5.

PMID:
24500604
39.

Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases.

Theibich A, Dreyer L, Magyari M, Locht H.

Clin Rheumatol. 2014 May;33(5):719-23. doi: 10.1007/s10067-013-2419-8. Epub 2013 Nov 8.

PMID:
24202614
40.

The opportunistic pathogen Propionibacterium acnes: insights into typing, human disease, clonal diversification and CAMP factor evolution.

McDowell A, Nagy I, Magyari M, Barnard E, Patrick S.

PLoS One. 2013 Sep 13;8(9):e70897. doi: 10.1371/journal.pone.0070897. eCollection 2013.

41.

Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study).

Magyari M, Bach Søndergaard H, Sellebjerg F, Soelberg Sørensen P.

Mult Scler Relat Disord. 2013 Apr;2(2):141-6. doi: 10.1016/j.msard.2012.10.001. Epub 2012 Dec 11.

PMID:
25877635
42.

Reproduction and the risk of multiple sclerosis.

Magyari M, Koch-Henriksen N, Pfleger CC, Sørensen PS.

Mult Scler. 2013 Oct;19(12):1604-9. doi: 10.1177/1352458513481397. Epub 2013 Mar 18.

PMID:
23508651
43.

Novel heterozygous nonsense mutation of the OPTN gene segregating in a Danish family with ALS.

Tümer Z, Bertelsen B, Gredal O, Magyari M, Nielsen KC, Lucamp, Grønskov K, Brøndum-Nielsen K.

Neurobiol Aging. 2012 Jan;33(1):208.e1-5. doi: 10.1016/j.neurobiolaging.2011.07.001. Epub 2011 Aug 26.

PMID:
21852022
44.

[Neurosarcoidosis--different manifestations].

Magyari M, Frederiksen J.

Ugeskr Laeger. 2010 Nov 29;172(48):3344-5. Danish.

PMID:
21118667
45.

Hydrolytic behavior of 5alpha-hydroxy-11beta- and 5beta-hydroxy-11alpha-substituted 19-norsteroids.

Francsics-Czinege E, Tuba Z, Molnár C, Horváth J, Csörgei J, Visky G, Balogh G, Mák M, Hegedus B, Magyari M, Horváth J.

Steroids. 2003 Oct;68(9):739-49.

PMID:
14625006
46.

[Iodine deficiency in cardiovascular diseases].

Molnár I, Magyari M, Stief L.

Orv Hetil. 1998 Aug 30;139(35):2071-3. Hungarian.

PMID:
9755626
47.

Mitochondrial mutation as a probable causative factor in familial progressive tubulointerstitial nephritis.

Zsurka G, Ormos J, Iványi B, Túri S, Endreffy E, Magyari M, Sonkodi S, Venetianer P.

Hum Genet. 1997 Apr;99(4):484-7.

PMID:
9099838
48.

[Prostacyclin-like activity modifying plasma factors in diabetic microangiopathy].

Magyari M, Túri S, Csanálosi-Németh M.

Fortschr Ophthalmol. 1990;87(3):269-73. German.

PMID:
2115854
49.

Plasma factors influencing prostacyclin-like activity in patients with diabetic microangiopathy.

Turi S, Magyari M, Nemeth M, Bereczky C.

Prostaglandins Leukot Essent Fatty Acids. 1988 Mar;31(3):107-11.

PMID:
3287394
50.

[Plasma factors influencing prostacyclin-like activity in diabetic microangiopathies].

Túri S, Magyari M, Csalánosiné NM.

Orv Hetil. 1987 Jun 21;128(25):1311-5. Hungarian. No abstract available.

PMID:
3302816

Supplemental Content

Loading ...
Support Center